Somatropin (Human Growth Hormone)
Recombinant human growth hormone (191 amino acids); e.g. GENOTROPIN, initial US approval 1987, for paediatric growth failure due to GHD, Prader-Willi syndrome, SGA, Turner syndrome, ISS, and adult GHD.
60-Second Scientific Briefing
Somatropin is recombinant human growth hormone, identical to the hormone made by the pituitary. Products such as GENOTROPIN (initial US approval 1987) are FDA-approved for children with growth failure due to growth hormone deficiency, Prader-Willi syndrome, being born small for gestational age, Turner syndrome or idiopathic short stature, and for adults with growth hormone deficiency. The label lists serious warnings, including risks in acute critical illness, tumour growth or recurrence, diabetes and raised intracranial pressure. Use for bodybuilding or anti-ageing is not approved and it is prohibited in sport.
🛒 Somatropin (Human Growth Hormone) products in the store (6) →
What is Somatropin (Human Growth Hormone)?
Pharmacological Classification & Molecular IdentitySomatropin is recombinant human growth hormone, a 191-amino-acid protein identical to pituitary growth hormone, given by injection. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
Verified Chemical & Regulatory Registry Identifiers
Mechanism of Action & Receptor Targets
Biological Pathway and Target BindingReceptor Selectivity: Binds the growth hormone receptor and stimulates the production of IGF-1, which mediates many of its effects on linear growth and on protein, fat and carbohydrate metabolism. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
Regulatory & FDA Approval Status
Legal and Regulatory ClassificationsFDA-approved (for example GENOTROPIN, initial US approval 1987) for children with growth failure due to growth hormone deficiency, Prader-Willi syndrome, small for gestational age without catch-up growth by age 2, Turner syndrome and idiopathic short stature, and for adults with adult- or childhood-onset growth hormone deficiency. Bodybuilding, athletic and anti-ageing uses are not approved, and growth hormone is prohibited at all times by WADA (section S2). [1] U.S. National Library of Medicine (DailyMed), 2026 ↗ [2] World Anti-Doping Agency, 2024 ↗
FDA-approved (for example GENOTROPIN, initial US approval 1987) for children with growth failure due to growth hormone deficiency, Prader-Willi syndrome, small for gestational age without catch-up growth by age 2, Turner syndrome and idiopathic short stature, and for adults with adult- or childhood-onset growth hormone deficiency. Bodybuilding, athletic and anti-ageing uses are not approved, and growth hormone is prohibited at all times by WADA (section S2).
Human Evidence & Clinical Trials
Clinical Study Readouts and Evidence SynthesesThe approved indications rest on clinical trials in each paediatric condition and in adults with growth hormone deficiency, summarised in the prescribing information. The label does not support use in people without these diagnoses. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
Clinical Evidence
The approved indications rest on clinical trials in each paediatric condition and in adults with growth hormone deficiency, summarised in the prescribing information. The label does not support use in people without these diagnoses.
Safety Profile & Clinical Limitations
Documented Adverse Events and Known UncertaintiesContraindicated in acute critical illness (after open-heart or abdominal surgery, multiple trauma or acute respiratory failure), in children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (sudden deaths reported), in active malignancy, in active proliferative or severe non-proliferative diabetic retinopathy, and in children with closed epiphyses. Warnings include second neoplasms in childhood cancer survivors (notably meningiomas after head radiation), impaired glucose tolerance and diabetes, intracranial hypertension, serious hypersensitivity, fluid retention (oedema, joint pain, carpal tunnel syndrome, especially in adults), hypothyroidism, hypoadrenalism, slipped capital femoral epiphysis and progression of scoliosis. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
In adults it is unknown whether there is any relationship between somatropin replacement therapy and central nervous system tumour recurrence (label). Benefit and safety for non-approved uses such as bodybuilding or anti-ageing are not established, and products outside regulated pharmacies may be counterfeit. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
Dose Approval Status
Commercial Dosing Status and Policy DirectivesApproved US labelling: dosing is individualised and weight-based, differs by indication and is adjusted to response and IGF-1 levels, as set out in each product's prescribing information. Dosing is set by the prescribing endocrinologist. [1] U.S. National Library of Medicine (DailyMed), 2026 ↗
Under Egypt Peptides medical governance policies, no personal dosages, titration intervals, cycles, stacking recommendations, or self-injection instructions may be provided for unapproved investigational compounds. Clinical study protocols represent controlled experimental research parameters exclusively.
What is Known vs. What is Unknown
Evidence Comparison and Clinical Evidence Boundaries✓ Confirmed Scientific Evidence
- Somatropin is recombinant human growth hormone, a 191-amino-acid protein identical to pituitary growth hormone, given by injection.
- Targets & Selectivity: Binds the growth hormone receptor and stimulates the production of IGF-1, which mediates many of its effects on linear growth and on protein, fat and carbohydrate metabolism.
- The approved indications rest on clinical trials in each paediatric condition and in adults with growth hormone deficiency, summarised in the prescribing information. The label does not support use in people without these diagnoses.
- Safety considerations: Contraindicated in acute critical illness (after open-heart or abdominal surgery, multiple trauma or acute respiratory failure), in children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment (sudden deaths reported), in active malignancy, in active proliferative or severe non-proliferative diabetic retinopathy, and in children with closed epiphyses. Warnings include second neoplasms in childhood cancer survivors (notably meningiomas after head radiation), impaired glucose tolerance and diabetes, intracranial hypertension, serious hypersensitivity, fluid retention (oedema, joint pain, carpal tunnel syndrome, especially in adults), hypothyroidism, hypoadrenalism, slipped capital femoral epiphysis and progression of scoliosis.
? Unknown / Under Ongoing Investigation
- In adults it is unknown whether there is any relationship between somatropin replacement therapy and central nervous system tumour recurrence (label). Benefit and safety for non-approved uses such as bodybuilding or anti-ageing are not established, and products outside regulated pharmacies may be counterfeit.
Verified Questions & Answers
10 Verified scientific answers with permanent anchor keysSomatropin is recombinant human growth hormone, identical to the pituitary hormone. It is an FDA-approved medicine for specific growth disorders in children and growth hormone deficiency in adults.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
It activates the growth hormone receptor and raises IGF-1, which drives growth and affects protein, fat and sugar metabolism.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
Yes, for specific indications: paediatric growth failure (growth hormone deficiency, Prader-Willi syndrome, small for gestational age, Turner syndrome, idiopathic short stature) and adult growth hormone deficiency. Bodybuilding and anti-ageing uses are not approved.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
- The Prohibited List (World Anti-Doping Agency, 2024-01-01)
The approved uses rest on clinical trials in each paediatric condition and in adult growth hormone deficiency, summarised in the prescribing information. The label does not support use in people without these diagnoses.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
The label contraindicates it in acute critical illness, active cancer, severe diabetic eye disease and some children with Prader-Willi syndrome, and warns of second tumours in childhood cancer survivors, diabetes, raised intracranial pressure, fluid retention, joint pain, carpal tunnel syndrome, hip problems in children and worsening scoliosis.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
What are the critical unknown safety aspects and clinical limitations of Somatropin (Human Growth Hormone)?
§In adults it is unknown whether replacement therapy affects brain tumour recurrence (label). Benefit and safety for bodybuilding or anti-ageing are not established, and products outside regulated pharmacies may be counterfeit.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
Approved US labelling: dosing is individualised and weight-based, differs by indication and is adjusted to response and IGF-1 levels, as set out in each product's prescribing information. Dosing is set by the prescribing endocrinologist.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
Per the GENOTROPIN prescribing information: refrigerate the powder at 2–8 °C, protected from light, without freezing; after mixing keep refrigerated for up to 28 days and do not shake.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
Yes. Growth hormone is prohibited at all times under section S2 (peptide hormones, growth factors and related substances) of the 2026 WADA Prohibited List, unless a therapeutic use exemption is granted.
- WADA Prohibited List (World Anti-Doping Agency)
Egypt Peptides publishes reviewed scientific reference monographs for documentation and research. The site does not give individual medical advice, preparation or injection instructions, combination protocols or off-label use instructions. Decisions about any medicine belong to the treating physician.
- GENOTROPIN (somatropin): prescribing information (U.S. National Library of Medicine (DailyMed), 2026-08-06)
Somatropin (Human Growth Hormone) available in Egypt
For research use onlyResearch products with the current store price and stock. The scientific information on this page describes published studies, not these products.
Authoritative Sources & Literature Registry
Regulatory dossiers, clinical trial registries, and published studiesGENOTROPIN (somatropin): prescribing information ↗
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765
The Prohibited List ↗
https://www.wada-ama.org/en/prohibited-list